{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:38:25Z","timestamp":1787701105368,"version":"build-2784847793"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2025-06655"],"award-info":[{"award-number":["2025-06655"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Research Council of Norway","doi-asserted-by":"publisher","award":["336567"],"award-info":[{"award-number":["336567"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006350","name":"Clas Groschinsky Memorial Foundation","doi-asserted-by":"publisher","award":["MF2552"],"award-info":[{"award-number":["MF2552"]}],"id":[{"id":"10.13039\/501100006350","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"publisher","award":["2018092"],"award-info":[{"award-number":["2018092"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"publisher","award":["2021091"],"award-info":[{"award-number":["2021091"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jhepr.2026.101875","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:35:58Z","timestamp":1777602958000},"page":"101875","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hepatic flares, their immune signatures, and ALT variability after nucleos(t)ide analogue cessation in HBeAg-negative hepatitis B"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9598-7129","authenticated-orcid":false,"given":"Marte","family":"Holmberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2190-4346","authenticated-orcid":false,"given":"Annika","family":"Niehrs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav","family":"Dalgard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6959-989X","authenticated-orcid":false,"given":"Nega","family":"Berhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2042-5797","authenticated-orcid":false,"given":"Hailemichael","family":"Desalegn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0461-4870","authenticated-orcid":false,"given":"Soo","family":"Aleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3133-2724","authenticated-orcid":false,"given":"Nina","family":"Weis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8566-7039","authenticated-orcid":false,"given":"Tore","family":"Stenstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1669-1032","authenticated-orcid":false,"given":"Lars","family":"Heggelund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Samuelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Normann","family":"Karlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Lindahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Kleppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anni Assing","family":"Winckelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Brugger-Synnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8505-9498","authenticated-orcid":false,"given":"Hans Erling","family":"Simonsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Svendsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0967-076X","authenticated-orcid":false,"given":"Niklas K.","family":"Bj\u00f6rkstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4499-0320","authenticated-orcid":false,"given":"Dag Henrik","family":"Reikvam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5966-7166","authenticated-orcid":false,"given":"Asgeir","family":"Johannessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.101875_bib1","series-title":"Global hepatitis report 2024: action for access in low- and middle-income countries","year":"2024"},{"key":"10.1016\/j.jhepr.2026.101875_bib2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101875_bib3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMra2211764","article-title":"New approaches to chronic hepatitis B","volume":"388","author":"Dusheiko","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101875_bib4","first-page":"1629","article-title":"Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis","volume":"71","author":"Hall","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2026.101875_bib5","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study","volume":"67","author":"Berg","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101875_bib6","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jhep.2022.12.018","article-title":"A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B","volume":"78","author":"van Bommel","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101875_bib7","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101875_bib8","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B Study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101875_bib9","article-title":"Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: a systematic review and meta-analysis","volume":"5","author":"Tseng","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101875_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2022.03.006","article-title":"A case of HBV-induced liver failure in the REEF-2 phase II trial: implications for finite treatment strategies in HBV \u2018cure\u2019","volume":"77","author":"Agarwal","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101875_bib11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/hep.29821","article-title":"Less can be more: a finite treatment approach for HBeAg-negative chronic hepatitis","volume":"68","author":"Lampertico","year":"2018","journal-title":"B Hepatol"},{"key":"10.1016\/j.jhepr.2026.101875_bib12","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.14309\/ajg.0000000000002176","article-title":"Withdrawal of long-term nucleotide analog therapy in chronic hepatitis B: outcomes from the withdrawal phase of the HBRN immune active treatment trial","volume":"118","author":"Feld","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101875_bib13","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jhep.2024.08.015","article-title":"Predictors of hepatic flares after nucleos(t)ide analogue cessation \u2013 results of a global cohort study (RETRACT-B study)","volume":"82","author":"Dongelmans","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101875_bib14","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3851\/IMP1866","article-title":"Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside\/nucleotide analogues","volume":"16","author":"Jaroszewicz","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhepr.2026.101875_bib15","article-title":"Utility of novel viral and immune markers in predicting HBV treatment endpoints: a systematic review of treatment discontinuation studies","volume":"5","author":"Zeng","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101875_bib16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/hep4.1626","article-title":"Pilot study using machine learning to identify immune profiles for the prediction of early virological relapse after stopping nucleos(t)ide analogues in HBeAg-negative CHB","volume":"5","author":"W\u00fcbbolding","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2026.101875_bib17","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"83","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101875_bib18","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/apt.18147","article-title":"Clinical trial: an open-label, randomised trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B","volume":"60","author":"Johannessen","year":"2024","journal-title":"Aliment Pharmacol Therapeut"},{"key":"10.1016\/j.jhepr.2026.101875_bib19","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S2468-1253(19)30344-9","article-title":"Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad","volume":"5","author":"Ghany","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101875_bib20","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/liv.15140","article-title":"Off-tenofovir hepatitis flares in HBeAg-negative patients occur earlier, more frequent and severe than those off-entecavir therapies","volume":"42","author":"Liu","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.101875_bib21","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1016\/j.cgh.2020.12.005","article-title":"Prediction of sustained response after nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels: a multicenter study (CREATE)","volume":"20","author":"Sonneveld","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101875_bib22","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.cgh.2022.07.005","article-title":"Differential relapse patterns after discontinuation of entecavir vs tenofovir disoproxil fumarate in chronic hepatitis B","volume":"21","author":"Choi","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101875_bib23","doi-asserted-by":"crossref","first-page":"21194","DOI":"10.1038\/s41598-021-00455-8","article-title":"Association between immunologic markers and cirrhosis in individuals with chronic hepatitis B","volume":"11","author":"Argirion","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2026.101875_bib24","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jhep.2005.05.034","article-title":"The RANKL\/OPG system and bone mineral density in patients with chronic liver disease","volume":"43","author":"Moschen","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101875_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-50216-y","article-title":"Treatment cessation in HBeAg-negative chronic hepatitis B: clinical response is associated with increase in specific proinflammatory cytokines","volume":"13","author":"Holmberg","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2026.101875_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.1052917","article-title":"CXCL8, CXCL9, CXCL10, and CXCL11 as biomarkers of liver injury caused by chronic hepatitis B","volume":"13","author":"Yu","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jhepr.2026.101875_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122268","article-title":"Cytokine and chemokine signatures associated with hepatitis B surface antigen loss in hepatitis B patients","volume":"3","author":"Yoshio","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jhepr.2026.101875_bib28","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1084\/jem.194.12.1755","article-title":"Blocking chemokine responsive to \u03b3\u20132\/interferon (IFN)-\u03b3 inducible protein and monokine induced by IFN-\u03b3 activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus\u2013specific cytotoxic T lymphocytes","volume":"194","author":"Kakimi","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.jhepr.2026.101875_bib29","doi-asserted-by":"crossref","first-page":"13717","DOI":"10.1073\/pnas.172521999","article-title":"Depletion of neutrophils blocks the recruitment of antigen-nonspecific cells into the liver without affecting the antiviral activity of hepatitis B virus-specific cytotoxic T lymphocytes","volume":"99","author":"Sitia","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2026.101875_bib30","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/infdis\/jiw412","article-title":"Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B","volume":"214","author":"H\u00f6ner Zu Siederdissen","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhepr.2026.101875_bib31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2019.08.024","article-title":"TNF-\u03b1\/IFN-\u03b3 profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection","volume":"72","author":"Wang","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101875_bib32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41419-020-2264-z","article-title":"The concentration of tumor necrosis factor-\u03b1 determines its protective or damaging effect on liver injury by regulating Yap activity","volume":"11","author":"Zhao","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jhepr.2026.101875_bib33","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/17474124.2022.2156338","article-title":"Hepatitis B flare: the good, the bad and the ugly","volume":"16","author":"Liaw","year":"2022","journal-title":"Expert Rev Gastroenterol Hepatol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926001461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926001461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T07:31:00Z","timestamp":1783582260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926001461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2589555926001461"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101875","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic flares, their immune signatures, and ALT variability after nucleos(t)ide analogue cessation in HBeAg-negative hepatitis B","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101875","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101875"}}